文献速递流行病学与生物统计真实世界研究与卫生经济

南非注射用来那卡帕韦用于HIV暴露前预防的优化推广:模型与经济评估

Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation.
PubMed 文献 · PLoS Med · 2026-07-21

研究使用Thembisa v4.8模型模拟2026-2045年南非LEN、TDF/FTC和CAB的推广,评估流行病学影响与成本效果。优先覆盖AGYW、MSM和FSW可最大化影响。

要点

  • LEN成本2301-3567美元/寿命年,优于TDF/FTC(8143)和CAB(11114-16118)。
  • ART 95%覆盖率节省寿命年是LEN的4.8-8倍,成本577美元/寿命年。

核心结论

  • 在南非向HIV高风险人群提供LEN比现有口服PrEP更具成本效果,可加速HIV发病率下降。
  • 优先覆盖最高风险人群对最大化影响和成本效果至关重要。

研究设计与样本

  • 使用Thembisa v4.8确定性 compartmental HIV传播模型,模拟2026-2045年南非LEN、TDF/FTC和CAB推广。
  • 模拟人群包括女性(含AGYW、FSW、PBFW)、MSM和异性恋男性。
  • 成本从南非政府视角以2025年美元未贴现呈现。

主要发现

  • LEN推广使发病率在2039-2043年降至<0.1%,比基线提前10-14年。
  • TDF/FTC和保守LEN推广使HIV项目成本增加3%,但LEN更具成本效果。
  • LEN成本为2301-3567美元/寿命年,TDF/FTC为8143美元/寿命年,CAB为11114-16118美元/寿命年。
  • ART 95%覆盖率挽回的寿命年是LEN的4.8-8倍,成本为577美元/寿命年。

关键数值与推荐

  • LEN保守场景启动率与TDF/FTC扩大相似,乐观场景为TDF/FTC扩大的两倍。
  • LEN使用时长保守场景6-12个月,乐观场景12-24个月。
  • 初始分配优先AGYW、MSM和FSW可最大化避免感染;全国推广优先FSW和MSM最具成本效果,FSW扩大下甚至成本节约。

临床怎么用

  • 在南非HIV预防中,LEN可作为口服PrEP的更具成本效果的替代,但需优先覆盖AGYW、MSM和FSW。
  • 决策者应权衡LEN与ART、安全套、检测和男性包皮环切等更具成本效果的干预。

局限性

  • 模型摄入量实现存在不确定性。
  • 长效产品的风险差异化摄入未充分建模。
  • 真实世界实施成本存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: South Africa accounts for 20% of global HIV infections. Six-monthly injectable lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) has superior efficacy to oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and similar efficacy to 2-monthly injectable cabotegravir (CAB). With LEN's regulatory approval, South Africa faces critical implementation decisions amid constrained domestic resources and reduced international funding. We evaluated the epidemiological impact, cost-effectiveness, and optimal populations for LEN roll-out in South Africa. METHODS AND FINDINGS: Using Thembisa v4.8, a deterministic compartmental HIV transmission model, we simulated the impact of LEN scale-up, expanded oral TDF/FTC, and CAB scale-up, compared to a baseline of current TDF/FTC provision over 20 years (2026-2045) in South Africa. We modelled PrEP among women, including adolescent girls and young women (AGYW), female sex workers (FSW), pregnant and breastfeeding women (PBFW), men who have sex with men (MSM), and heterosexual men. For TDF/FTC scale-up, we doubled baseline initiation rates. For LEN and CAB, conservative and optimistic scenarios assumed initiation rates similar to or double those under TDF/FTC scale-up, respectively. Duration of use varied by subpopulation under TDF/FTC (3-6 months), conservative (LEN: 6-12 months, CAB: 4-8 months), and optimistic (LEN: 12-24 months, CAB: 8-16 months) scenarios. We modelled strategies to maximise impact of ~500,000 LEN doses allocated for 2026-2027, and national roll-out by subpopulations. We compared LEN cost-effectiveness to other HIV interventions, including antiretroviral treatment (ART). Costs are presented from the South African government's perspective in undiscounted 2025 United States Dollars (USD). Providing LEN to 1.7-2.9 million South Africans annually averted 19%-31% of infections and saved 3%-5% of life years lost to HIV, reaching incidence <0.1% in 2039-2043, 10-14 years earlier than baseline. TDF/FTC and conservative LEN scale-up increased HIV programme costs by 3%; however, LEN was more cost-effective, costing $2,301-$3,567/life year saved (LYS) versus $8,143/LYS (TDF/FTC scale-up) and $11,114-$16,118/LYS (CAB). While promising for HIV prevention, scaling up condoms, ART, HIV testing, and medical male circumcision may be more cost-effective than LEN; notably ART at 95% coverage, saved 4.8-8-fold more life years compared to LEN, costing $577/LYS. Prioritising AGYW, MSM, and FSW for the initial allocation maximised infections averted, while national roll-out prioritising FSW and MSM were most cost-effective, and even cost-saving under scale-up to FSW. Study limitations include uncertainty in achieving modelled uptake, risk-differentiated uptake of long-acting products, and real-world implementation costs. CONCLUSIONS: Delivering LEN to persons with elevated HIV risk in South Africa is more cost-effective than existing oral PrEP and can speed up HIV incidence reduction. Prioritising uptake among groups at highest risk is essential to maximise impact and cost-effectiveness.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jamieson L, Johnson LF, Imai-Eaton JW, et al. Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation. PLoS Med. 2026. PMID: 42479779. doi:10.1371/journal.pmed.1004882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。